Has Nicholas Avitabile, MD received payments from drug or device companies?

Yes. Drug and device makers reported $422 in general payments to Nicholas Avitabile, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nicholas Avitabile, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nicholas Avitabile, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nicholas Avitabile, MD

Endocrinology, Diabetes & Metabolism · Monroe, NYNPI 1750607602

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $303 of the $422 with a category attached, or 71.8%. 3 manufacturers reported payments, led by AbbVie at 59.4% of the total. 2025 is the largest year on record at $250, 4.8 times the $53 reported in 2020. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NY, where the typical reported total is $1,058.

$422in general payments, 2019–2025

Across 5 payments — averaging $84.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$250
Mannkind Corporation$119
Medtronic$53

$14,200in research payments, 2019–2025

Across 1 payment — averaging $14,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$14K

What the payments were for

Food & beverage$30372%
Gifts$11928%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	2	$250
Mannkind Corporation	2	$119
Medtronic	1	$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$250

How this compares

$422 in reported general payments places this provider in the 35th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024

$693,700

Medicare patients

845

Services billed

29,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	644	$865,500
TrulicityDulaglutide	277	$372,875
MounjaroTirzepatide	316	$363,787
JardianceEmpagliflozin	241	$272,343
FarxigaDapagliflozin Propanediol	180	$197,753
Tresiba Flextouch U-200Insulin Degludec	82	$169,885
JanuviaSitagliptin Phosphate	116	$142,786
TradjentaLinagliptin	103	$100,505
Synjardy XrEmpagliflozin/Metformin Hcl	66	$77,498
GlyxambiEmpagliflozin/Linagliptin	52	$64,620
Janumet XrSitagliptin Phos/Metformin Hcl	52	$63,664
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	38	$58,526
Tresiba Flextouch U-100Insulin Degludec	53	$55,159
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	92	$49,853
Xigduo XrDapaglifloz Propaned/Metformin	46	$47,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieSynthroid	$250	$24,262305 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in Monroe

Robert BuschAlbany$2.7M
Michael ShanikSmithtown$1.2M
Ajay ChaudhuriBuffalo$888K
Vinay KapoorManhasset$820K
John BilezikianNew York$809K
Barbara HirschManhasset$746K
Martin GrajowerBronx$713K
Anastasios ManessisNew York$656K
Jonas LeibowitzYonkers$613K
Philip OtterbeckStaten Island$575K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →